Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099466 | 0.83 | P2RX3 (0.40) | P2RX3ACACBMEN1KMT2AFFAR1 | |
| SCHEMBL12100034 | 0.83 | MAPK14 (0.48) | GPR6ACACBKCNH2HRH3FFAR1 | |
| SCHEMBL12099455 | 0.82 | KCNH2 (0.45) | GPR6ACACBKCNH2HRH3FFAR1 | |
| SCHEMBL12099598 | 0.81 | MAPK14 (0.44) | P2RX3GPR6ACACBMEN1KMT2A | |
| SCHEMBL12100012 | 0.81 | FFAR4 (0.39) | P2RX3ACACBKCNH2HRH3FFAR1 | |
| SCHEMBL12099593 | 0.77 | ALDH1A1 (0.45) | GPR6KCNH2HRH3MEN1KMT2A | |
| SCHEMBL12099601 | 0.74 | MAPK14 (0.48) | GPR6ACACBKCNH2HRH3MEN1 | |
| SCHEMBL12099719 | 0.73 | GPR6 (0.39) | GPR6ACACBKCNH2MEN1KMT2A | |
| SCHEMBL12099441 | 0.73 | EPHX2 (0.44) | ACACBKCNH2HRH3FFAR1CHRM4 | |
| SCHEMBL12100236 | 0.72 | ACACB (0.41) | ACACBKCNH2HRH3PDE10AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | P2RX3 109/4885GPR6 722/4885ACACB 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.